Philips' Fetal-Maternal Monitors Designed with Clinicians and Patients in Mind

Royal Philips ElectronicsRoyal Philips Electronics (NYSE: PHG, AEX: PHI) today announced the release of its Avalon FM40 and FM50 fetal-maternal monitors. The Avalon FM40 and FM50 are the newest additions to the Avalon family of fetal-maternal products, which includes the Avalon Cordless Transducer System (CTS) and the Avalon FM20 and FM30 fetal-maternal monitors.

These innovative monitors can feature a one-of-a-kind external display with touch-screen capability that customers can choose as an option in addition to the monitor's built-in, 6.5 inch color, touch-screen display. This larger external display, which comes in various sizes, can be mounted across the room, on a furniture cart in the labor and delivery room, or other convenient locations. This makes the monitors easier for clinicians to use because it allows them to interact with the fetal monitor even when they are not at the patient's bedside.

The new monitors were specifically designed with clinicians and patients in mind. "We constantly seek feedback from our customers, who told us they needed new, advanced features in a fetal monitor with the ability to maximize their investment by utilizing existing cart furniture," said David Russell, vice president of global marketing for Patient Monitoring, Philips Healthcare. "By creating the Avalon FM40 and FM50 with a familiar footprint, combined with new, cutting-edge technology and the patient-centric design of the Avalon family, we are fully equipped to meet this need."

Philips understands that patient comfort is extremely important, so the Avalon transducers are constructed with a softer material which adds to the comfort of the mother during antepartum and labor and delivery monitoring. The large, external display allows the family of the patient to become more involved in the birth experience since they can more easily view what is going on at all times; and for obstetricians and nurse/midwives to be able to view pertinent patient information at a distance. The ability to interface the FM40 and FM50 with the Avalon Cordless Transducer System (CTS) allows the mother to be mobile while she and her baby are being continuously monitored.

The Philips Avalon FM40 and FM50 provide clinicians with advanced, intuitive technologies to care for expectant mothers and their babies. As with the rest of the Avalon fetal-maternal monitoring family, vital patient data is continuously captured by the built-in data buffer system with the added capability of selective data printout, which reduces the risk of data loss. The monitors also feature "smart" transducers with universal plug and play connectors to enhance ease of use. Replacement parts, such as the cables, can be exchanged easily without having to replace an entire unit, reducing the cost of service.

The Philips Avalon FM40 antepartum monitor provides an extensive set of external monitoring capabilities, such as external monitoring of uterine activity, up to three fetal heart rates and fetal movement profile (FMP) via ultrasound. The Avalon FM50 intrapartum monitor includes the external monitoring capabilities of the FM40 and internal fetal measurements including fetal heart rate via direct fetal ECG and intrauterine pressure. Both monitors provide monitoring of maternal blood pressure, SpO2, maternal ECG and maternal heart rate. Both fetal and maternal ECG waves can be displayed on the screen. These new high-end intrapartum and antepartum monitors easily integrate with Philips' obstetrical information system, OB TraceVue, as well as other information systems.

"Fetal monitoring is the standard of care in most modern labor and delivery care settings the world over, but with increasing multiple births, monitoring of twins and triplets is now a required functionality," said Russell. "Like the Avalon FM20 and FM30, the FM40 and FM50 can monitor up to three babies and the mother simultaneously while providing cross channel verification to discriminate between maternal and separate fetal heart rates. Philips is the only provider of non-invasive triplet monitoring in one device."

Russell continued, "The newest addition to the Avalon family further enhances care-givers' ability to provide quality care in a more patient-focused environment by providing advanced monitoring that is extremely intuitive. The capabilities of the Philips fetal-maternal monitoring portfolio help healthcare facilities to differentiate their services and provide expectant mothers with high quality obstetrical care."

About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products, services and solutions through the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide. With sales of EUR 27 billion in 2007, the company is a market leader in medical diagnostic imaging and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions for personal wellbeing. News from Philips is located at www.philips.com/newscenter.

Most Popular Now

SPARK TSL Acquires Sentean Group

SPARK TSL is acquiring Sentean Group, a Dutch company with a complementary background in hospital entertainment and communication, and bringing its Fusion Bedside platform for clinical and patient apps to...

Can AI Techniques Help Clinicians Assess…

Investigators have applied artificial intelligence (AI) techniques to gait analyses and medical records data to provide insights about individuals with leg fractures and aspects of their recovery. The study, published in...

Standing Up for Health Tech and SMEs: Sh…

AS the new chair of the health and social care council at techUK, Shane Tickell talked to Highland Marketing about his determination to support small and innovative companies, by having...

GPT-4 Matches Radiologists in Detecting …

Large language model GPT-4 matched the performance of radiologists in detecting errors in radiology reports, according to research published in Radiology, a journal of the Radiological Society of North America...

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Experts Propose Specific and Suited Guid…

Current Artificial Intelligence (AI) models for cancer treatment are trained and approved only for specific intended purposes. GMAI models, in contrast, can handle a wide range of medical data including...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...